Cargando…

Long way to go: Progress of orphan drug accessibility in China from 2017 to 2022

Introduction: Over 400 million patients worldwide suffer from rare diseases. Access to orphan drugs is, therefore, crucial for this population. China has been actively working on improving orphan drug accessibility in the past decades, especially since 2018 when the First National List of Rare Disea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Jia, Yu, Yue, Zhong, Mingkang, Ma, Chunlai, Shao, Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031016/ https://www.ncbi.nlm.nih.gov/pubmed/36969835 http://dx.doi.org/10.3389/fphar.2023.1138996

Ejemplares similares

Availability and Accessibility of Orphan Medicinal Products to Patients in Slovakia in the Years 2010–2019
por: Foltanova, Tatiana, et al.
Publicado: (2022)

Chinese Medicines for Preventing and Treating Radiation-Induced Pulmonary Injury: Still a Long Way to Go
por: Ding, Yan, et al.
Publicado: (2019)

Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
por: Eichler, Hans-Georg, et al.
Publicado: (2023)

Comprehensive insights into the function and molecular and pharmacological regulation of neuron-derived orphan receptor 1, an orphan receptor
por: Hong, Hongxiang, et al.
Publicado: (2022)

Advancements in therapeutically targeting orphan GPCRs
por: Stockert, Jennifer A., et al.
Publicado: (2015)

Editorial: Orphan GPCRs As Emerging Drug Targets
por: Fang, Ye, et al.
Publicado: (2015)

Orphan Drugs, Compounded Medication and Pharmaceutical Commons
por: Hendrickx, Kim, et al.
Publicado: (2021)

The histamine H(4) receptor: from orphan to the clinic
por: Thurmond, Robin L.
Publicado: (2015)

The Guanine-Based Purinergic System: The Tale of An Orphan Neuromodulation
por: Di Liberto, Valentina, et al.
Publicado: (2016)

Crowd Funding for Orphan Drugs: The Case of Baby Pia
por: Pinxten, Wim
Publicado: (2021)

Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2021)

The therapeutic potential of orphan GPCRs, GPR35 and GPR55
por: Shore, Derek M., et al.
Publicado: (2015)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019)

Orphan medical devices have come a long way
por: Dooms, M.
Publicado: (2023)

Targeting Orphan Nuclear Receptors NR4As for Energy Homeostasis and Diabetes
por: Zhang, Chenyang, et al.
Publicado: (2020)

Editorial: Insights in ethnopharmacology: 2022
por: Kim, Cheorl-Ho, et al.
Publicado: (2023)

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019)

How to Value Orphan Drugs? A Review of European Value Assessment Frameworks
por: Blonda, Alessandra, et al.
Publicado: (2021)

Assesment of Adulterated Traditional Chinese Medicines in China: 2003-2017
por: Xu, Mingzhe, et al.
Publicado: (2019)

Myeloma: A Lot of Progress, Still a Long Way to Go
por: Mikala, Gábor, et al.
Publicado: (2021)

Go with the flow: de-orphaning focused combinatorial libraries
por: Reutlinger, Michael, et al.
Publicado: (2014)

Access to Orphan Drugs is a Challenge for Sustainable Management of Cystinosis in China
por: Li, Xiao-Qiao, et al.
Publicado: (2018)

Evaluation and Application of Population Pharmacokinetic Models for Identifying Delayed Methotrexate Elimination in Patients With Primary Central Nervous System Lymphoma
por: Mao, Junjun, et al.
Publicado: (2022)

The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy
por: Xoxi, Entela, et al.
Publicado: (2021)

Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review
por: Abdallah, Khadidja, et al.
Publicado: (2021)

Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study
por: Gorini, Francesca, et al.
Publicado: (2022)

Trends in orphan drug use and spending among children and adolescents during 2010–2020 in Korea
por: Oh, Jung Yeon, et al.
Publicado: (2022)

The end of HIV: Still a very long way to go, but progress continues
por: Deeks, Steven G., et al.
Publicado: (2017)

Accessibility of Essential Medicines for Children in Sichuan Province of China: A Cross-Sectional Study
por: Chen, Zhe, et al.
Publicado: (2022)

Mechanism of coordinated access to orphan drugs
por: DeRidder, R, et al.
Publicado: (2012)

Patient access to orphan drugs in France
por: Bourdoncle, Marion, et al.
Publicado: (2019)

Piperlongumine is a ligand for the orphan nuclear receptor 4A1 (NR4A1)
por: Zhang, Lei, et al.
Publicado: (2023)

Going separate ways
por: Leslie, Mitch
Publicado: (2001)

Way to go, RNA
por: Belasco, Joel G.
Publicado: (2015)

Applying machine learning to the pharmacokinetic modeling of cyclosporine in adult renal transplant recipients: a multi-method comparison
por: Mao, Junjun, et al.
Publicado: (2022)

Making Sure That Orphan Incentives Tip the Right Way in Europe
por: Horgan, Denis, et al.
Publicado: (2022)

Improving the quality of pediatric clinical practice guidelines in China: a long way to go
por: Liu, Ya-Li, et al.
Publicado: (2021)

What Factors Hindered the Access to Essential Anticancer Medicine in Public Hospitals for the Local Population in Hubei Province, China
por: Chen, Chaoyi, et al.
Publicado: (2021)

Comparing access to orphan medicinal products in Europe
por: Zamora, Bernarda, et al.
Publicado: (2019)

Analysis of patient access to orphan drugs in Turkey
por: Koçkaya, Güvenç, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fife7ds6cqo1t6i9qdhqbetatl